

Adult CIRB - Early Phase Emphasis Meeting Agenda

August 18, 2020

I Continuing Review

10005, A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma (Protocol Version Date 07/28/20)

II Continuing Review

10181, A Phase 2 Study of Savolitinib in Subjects with MET Amplified Metastatic Colorectal Cancer (Protocol Version Date 05/19/20)

III Continuing Review

10301, A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (Protocol Version Date 07/17/20)

IV Continuing Review

9892, Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer (Protocol Version Date 05/17/19)

V Continuing Review

9938, Phase I clinical trial of M6620 in combination with the topoisomerase I inhibitor irinotecan in patients with advanced solid tumors (Protocol Version Date 06/30/20)



FOR THE NATIONAL CANCER INSTITUTE

VI New Study - Initial Review

10387, Pilot Trial of Nivolumab plus Cabozantinib for Advanced Solid Tumors in Patients with HIV infection (Protocol Version Date 07/07/20)

VII New Study - Initial Review

10402, BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA) (Protocol Version Date 07/27/20)

VIII Amendment

10020, A Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer (Protocol Version Date 07/15/20)
